Why Is Shattuck Labs Stock Falling In Pre-market?

October 01, 2024 — 07:18 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Shattuck Labs (STTK) announced a strategic pipeline prioritization to include the discontinuation of its clinical program, SL-172154. The company will turn its focus to SL-325, its DR3 antagonist antibody. Shattuck has implemented a restructuring plan to prioritize the development of the DR3 program. Approximately 40% of workforce will be impacted by the changes.

"We are disappointed that the promising complete remission rates we previously shared from our Phase 1 clinical trial did not translate to clinically meaningful improvements in median overall survival for TP53m AML and HR-MDS patients treated with SL-172154 in combination with azacitidine," said Taylor Schreiber, CEO.

The company believes its cash and cash equivalents and investments will be sufficient to fund its planned operations into 2027, beyond results from planned Phase 1 clinical trial of SL-325. As of June 30, 2024, cash and cash equivalents and investments were $105.3 million.

Shares of Shattuck Labs are down 50% in pre-market trade on Tuesday.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Why Is Shattuck Labs Stock Falling In Pre-market?

Tags

Latest Articles